Cocaine inhibits GABA release in the VTA through endogenous 5-HT.
The ventral tegmental area (VTA) is thought to be involved in the addictive properties of many drugs, including cocaine. It has been hypothesized that cocaine exerts its actions in the VTA by blocking the reuptake of dopamine released from the dendrites of the A10 dopamine neurons, thus prolonging the actions of dopamine at D2 autoreceptors. However, cocaine also blocks the reuptake of the other monoamines, including serotonin (5-HT). Using intracellular recordings from midbrain dopamine neurons in a brain slice preparation, we have found that cocaine (0.1-10 microM) inhibited the GABAB IPSP in a dose-dependent manner. This effect was observed in the presence of the D2 dopamine receptor antagonists sulpiride (1 microM) and eticlopride (0.1 microM). 5-HT mimicked this effect, as did the selective 5-HT1D receptor agonist sumatriptan and the 5-HT-releasing agent fenfluramine. The actions of both 5-HT and cocaine were attenuated by the 5-HT1C/D antagonist metergoline. Pretreatment of slices with the 5-HT-depleting agent p-chloroamphetamine (pCA; 10 microM) abolished the inhibition of the GABAB IPSP by cocaine but failed to affect the actions of sumatriptan. We conclude that cocaine acts to modulate the GABA input to A10 dopamine neurons via inhibition of the 5-HT transporter, increasing the concentration of 5-HT at presynaptic 5-HT1D receptors. These actions of cocaine were apparent at lower concentrations than those required to act via inhibition of the dopamine transporter. This reduction of inhibitory synaptic input into the VTA would be expected to attenuate the GABA-mediated feedback inhibition from the nucleus accumbens, thus leading to increased activation of dopamine neurons.
Cameron
D L
DL
Vollum Institute for Advanced Biomedical Research, Oregon Health Sciences University, Portland 97201.
Williams
J T
JT
D000818:Animals; D003042:Cocaine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004594:Electrophysiology; D005277:Fenfluramine / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D009474:Neurons / Q000502:physiology; D017729:Presynaptic Terminals / Q000187:drug effects; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D009435:Synaptic Transmission; D013681:Tegmentum Mesencephali / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D005680:gamma-Aminobutyric Acid / Q000502:physiology; D010133:p-Chloroamphetamine / Q000494:pharmacology
D018756:GABA Antagonists; D005277:Fenfluramine; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D010133:p-Chloroamphetamine; D003042:Cocaine; D004298:Dopamine